Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance:: A meta-analysis of randomized, controlled trials

被引:151
作者
Bliziotis, IA
Samonis, G
Vardakas, KZ
Chrysanthopoulou, S
Falagas, ME
机构
[1] Henry Dunant Hosp, Alfa Inst Biomed Sci, Athens, Greece
[2] Henry Dunant Hosp, Dept Med, Athens, Greece
[3] Univ Crete, Dept Med, Sch Med, Iraklion, Greece
[4] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
D O I
10.1086/430912
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The addition of an aminoglycoside to a Beta-lactam therapy regimen has been suggested to have a beneficial effect in delaying or preventing the development of antimicrobial resistance. We studied the effect of aminoglycoside/beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of resistance. Methods. We performed a meta-analysis of randomized, controlled trials (RCTs) that compared aminoglycoside/beta-lactam combination therapy with beta-lactam monotherapy and that reported data regarding the emergence of resistance (primary outcome) and/or development of superinfection, treatment failure, treatment failure attributable to emergence of resistance, treatment failure attributable to superinfection, all-cause mortality during treatment, and mortality due to infection. Data for this meta-analysis were identified from the PubMed database, Current Contents database, Cochrane central register of controlled trials, and references in relevant articles. Results. A total of 8 RCTs were included in the analysis. beta-Lactam monotherapy was not associated with a greater emergence of resistance than was the aminoglycoside/b-lactam combination (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.56 - 1.47). Actually, beta-lactam monotherapy was associated with fewer superinfections (OR, 0.62; 95% CI, 0.42 - 0.93) and fewer treatment failures (OR, 0.62; 95% CI, 0.38 - 1.01). Rates of treatment failure attributable to emergence of resistance (OR, 3.09; 95% CI, 0.75 - 12.82), treatment failure attributable to superinfection (OR, 0.60; 95% CI, 0.33 - 1.10), all-cause mortality during treatment (OR, 0.70; 95% CI, 0.40 - 1.25), and mortality due to infection (OR, 0.74; 95% CI, 0.46 - 1.21) did not differ significantly between the 2 regimens. Conclusions. Compared with b-lactam monotherapy, the aminoglycoside/beta-lactam combination was not associated with a beneficial effect on the development of antimicrobial resistance among initially antimicrobial-susceptible isolates.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 85 条
  • [71] Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci
    Sexton, DJ
    Tenenbaum, MJ
    Wilson, WR
    Steckelberg, JM
    Tice, AD
    Gilbert, D
    Dismukes, W
    Drew, RH
    Durack, DT
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 27 (06) : 1470 - 1474
  • [72] RANDOMIZED EVALUATION OF CEFTAZIDIME OR TICARCILLIN AND TOBRAMYCIN FOR THE TREATMENT OF OSTEOMYELITIS CAUSED BY GRAM-NEGATIVE BACILLI
    SHEFTEL, TG
    MADER, JT
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (01) : 112 - 115
  • [73] Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: A randomized study
    Sieger, B
    Berman, SJ
    Geckler, RW
    Farkas, SA
    [J]. CRITICAL CARE MEDICINE, 1997, 25 (10) : 1663 - 1670
  • [74] CEFOTAXIME COMPARED WITH NAFCILLIN PLUS TOBRAMYCIN FOR SERIOUS BACTERIAL-INFECTIONS - A RANDOMIZED, DOUBLE-BLIND TRIAL
    SMITH, CR
    AMBINDER, R
    LIPSKY, JJ
    PETTY, BG
    ISRAEL, E
    LEVITT, R
    MELLITS, ED
    ROCCO, L
    LONGSTRETH, J
    LIETMAN, PS
    [J]. ANNALS OF INTERNAL MEDICINE, 1984, 101 (04) : 469 - 477
  • [75] SAFETY AND EFFICACY OF MEROPENEM IN PATIENTS WITH SEPTICEMIA - A RANDOMIZED COMPARISON WITH CEFTAZIDIME, ALONE OR COMBINED WITH AMIKACIN
    SOLBERG, CO
    SJURSEN, H
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 : 157 - 166
  • [76] SOLOMKIN JS, 1986, CLIN THER, V9, P123
  • [77] Efficacy, safety, and tolerance of piperacillin/tazobactam compared to co-amoxiclav plus an aminoglycoside in the treatment of severe pneumonia
    Speich, R
    Imhof, E
    Vogt, M
    Grossenbacher, M
    Zimmerli, W
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1998, 17 (05) : 313 - 317
  • [78] RANDOMIZED PROSPECTIVE-STUDY COMPARING MOXALACTAM AND CEFOXITIN WITH OR WITHOUT TOBRAMYCIN FOR THE TREATMENT OF SERIOUS SURGICAL INFECTIONS
    TALLY, FP
    KELLUM, JM
    HO, JL
    ODONNELL, TF
    BARZA, M
    GORBACH, SL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (02) : 244 - 249
  • [79] THOMPSON JE, 1993, SURG GYNECOL OBSTET, V177, P30
  • [80] MICROBIOLOGY AND THERAPY OF ACUTE PELVIC INFLAMMATORY DISEASE IN HOSPITALIZED-PATIENTS
    THOMPSON, SE
    HAGER, WD
    WONG, KH
    LOPEZ, B
    RAMSEY, C
    ALLEN, SD
    STARGEL, MD
    THORNSBERRY, C
    BENIGNO, BB
    THOMPSON, JD
    SHULMAN, JA
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1980, 136 (02) : 179 - 186